Clearpoint Neuro IncNASDAQ:CLPT
- LAST PRICE11.4634
- TODAY'S CHANGE (%)0.3734 (3.3670%)
- Bid / Lots11.4600/ 7
- Ask / Lots11.5000/ 20
- Open / Previous Close11.1900 / 11.0900
- Day Range
- 52 Week Range
- Volume97,537
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLPT |
|---|---|---|
| 09:32 ET | 2094 | 11.19 |
| 09:35 ET | 200 | 11.17 |
| 09:37 ET | 200 | 11.1793 |
| 09:39 ET | 300 | 11.114 |
| 09:44 ET | 100 | 11.18 |
| 09:55 ET | 1662 | 11.14 |
| 10:02 ET | 1906 | 11.095 |
| 10:04 ET | 400 | 11.12 |
| 10:06 ET | 1800 | 11 |
| 10:08 ET | 716 | 11.04 |
| 10:11 ET | 1843 | 11.05 |
| 10:13 ET | 242 | 11 |
| 10:15 ET | 589 | 11 |
| 10:18 ET | 708 | 11.04 |
| 10:20 ET | 1000 | 11.06 |
| 10:22 ET | 200 | 11.05 |
| 10:27 ET | 200 | 11.075 |
| 10:29 ET | 569 | 11.05 |
| 10:33 ET | 300 | 11.11 |
| 10:38 ET | 516 | 11.12 |
| 10:40 ET | 1710 | 11.18 |
| 10:42 ET | 100 | 11.205 |
| 10:44 ET | 4250 | 11.33 |
| 10:45 ET | 800 | 11.33 |
| 10:47 ET | 3150 | 11.39 |
| 10:49 ET | 400 | 11.38 |
| 10:51 ET | 6500 | 11.36 |
| 10:54 ET | 900 | 11.31 |
| 10:56 ET | 300 | 11.35 |
| 10:58 ET | 1332 | 11.33 |
| 11:00 ET | 200 | 11.315 |
| 11:02 ET | 500 | 11.32 |
| 11:03 ET | 400 | 11.35 |
| 11:05 ET | 400 | 11.31 |
| 11:07 ET | 300 | 11.355 |
| 11:09 ET | 1164 | 11.38 |
| 11:12 ET | 1600 | 11.42 |
| 11:14 ET | 400 | 11.44 |
| 11:16 ET | 4147 | 11.465 |
| 11:18 ET | 9770 | 11.43 |
| 11:20 ET | 7559 | 11.44 |
| 11:21 ET | 3721 | 11.425 |
| 11:23 ET | 4611 | 11.49 |
| 11:25 ET | 598 | 11.47 |
| 11:27 ET | 2500 | 11.4405 |
| 11:30 ET | 608 | 11.47 |
| 11:32 ET | 1300 | 11.4634 |
Nov 13, 2024
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain, from 6:16PM ET on Wednesday Nov 13, 2024 by Dow Jones
6:16PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
ClearPoint Neuro Reports Third Quarter 2024 Results, from 4:13PM ET on Thursday Nov 07, 2024 by Dow Jones
4:13PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024, from 4:06PM ET on Thursday Oct 31, 2024 by Dow Jones
4:06PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clearpoint Neuro Inc | 305.9M | -16.6x | --- |
Nano-X Imaging Ltd | 360.3M | -6.4x | --- |
Stereotaxis Inc | 173.5M | -7.5x | --- |
Sensus Healthcare Inc | 146.4M | 15.3x | --- |
MaxCyte Inc | 363.9M | -10.3x | --- |
Atlantic International Corp | 253.2M | -0.9x | --- |
Company Information
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Contact Information
- Headquarters
- 120 S. SIERRA AVENUE, SUITE 100SOLANA BEACH, CA, United States 92075
- Phone
- 949-900-6833
- Fax
- 949-900-6834
Executives
- Independent Chairman of the Board
- R. John Fletcher
- President, Chief Executive Officer, Director
- Joseph Burnett
- Chief Financial Officer
- Danilo D' Alessandro
- Chief Operating Officer
- Mazin Sabra
- Chief Business Officer
- Jeremy Stigall
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $305.9M |
|---|---|
Revenue (TTM) | $30.4M |
Shares Outstanding | 27.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-0.69 |
Book Value | $0.86 |
P/E Ratio | -16.6x |
Price/Sales (TTM) | 10.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
